VigiLanz Pharmacy Surveillance

VigiLanz Pharmacy Surveillance is designed to empower pharmacists by providing near real-time clinical support to anticipate, prevent, and address adverse drug events, thereby improving patient care. This software reduces the need for manual reviews and enhances patient safety through smarter alerts and faster interventions.

For small or critical access hospitals, the VigiLanz Pharmacy Surveillance Starter simplifies antimicrobial use and resistance (AUR) reporting and submission, improving antimicrobial oversight without adding extra workload. It supports compliance with Joint Commission and CMS standards for Antibiotic Use (AU) and Antibiotic Resistance (AR) reporting.

In acute care facilities, the software leverages rule-based AI to standardize practices, boost clinical productivity, and enhance patient care. The Pro version offers advanced features and analytics for deeper insights, better documentation, and stronger system-wide stewardship.

For ambulatory care, the software helps pharmacy teams identify medication risks sooner, preventing costly events and improving patient safety across outpatient settings. It provides clear, actionable insights at the point of care to support confident and consistent care decisions.

Key Features:

• Near real-time alerts and AI-powered surveillance to prevent adverse drug events.
• Prioritized worklists and intuitive rounding tools to boost pharmacist efficiency.
• Timely alerts for drug-bug mismatches and de-escalation needs.
• Advanced reporting tools to track performance and support stewardship goals.
• Integration with EHR for faster action and response.

The software transforms complex patient data into actionable alerts, helping pharmacists intervene faster and reduce risks. It provides access to clinical data from various care settings, including ADT, eMAR, labs, and medication history. With flexible, rule-based AI, it surfaces urgent medication risks quickly, allowing pharmacy teams to focus on preventing harm.

Additional capabilities include monitoring pediatric patients at risk for AKI from nephrotoxic drugs and optimizing dosing accuracy and safety. The software is supported by clinical experts who assist with rule-building, training, and ongoing support.